P. E. Roy, Aritra Khan, Ipsita Chakravarti
Disease related malnutrition remains a major problem in hospitalized and critical patients, contributing significantly to prolonged hospitalization; prone to susceptibility to infections, delayed wound healing, muscle wasting, and increased mortality. Optimizing nutritional therapy has therefore become an important component of multidisciplinary clinical care. High-protein, peptide based nutritional supplements have gained an attention because they are designed to improve nutrient absorption rate, preserve lean body mass, support gastrointestinal tolerance, and enhance metabolic recovery. Among these specialized formula supplementation, OriPro 2.0 is a high calorie, high protein, peptide based oral and enteral supplement formulated with whey protein hydrolysate, concentrated whey protein, medium-chain triglycerides, dietary fiber, prebiotics, vitamins and minerals. This review summarizes current scientific evidence regarding the nutritional composition, physiological function, glycemic characteristics, and potential clinical applications of OriPro 2.0. Particular importance is placed on the role of peptide based nutrition in critically ill patients, individuals with gastrointestinal dysfunction, postoperative patients, geriatrics with sarcopenia, and patients experiencing disease-related malnutrition. Available evidence indicates that peptide-based formulations improve protein digestion, amino acid absorption, nitrogen balance, and gastrointestinal tolerance compared with conventional polymeric formulas in particular patient populations. Furthermore, the glycemic index study of OriPro 2.0 showed a low GI value (36±5), suggesting that the formulation may contribute to improved postprandial glucose control while maintaining adequate caloric and protein intake. The combination of derived peptides from whey, complex carbohydrates, medium chain triglycerides, soluble fiber, and micronutrients provides strong physiological functions for its use in medical nutrition therapy. However, despite promising nutritional characteristics, direct clinical evidence evaluating OriPro 2.0 remains limited. Most available data supporting peptide-based nutrition originate from studies evaluating similar formulations rather than OriPro 2.0 itself. Large multicenter randomized controlled trials are therefore required to establish its efficacy, safety, cost effectiveness, and prolong clinical outcomes across varieties of patients. Overall, OriPro 2.0 represents a promising specialized nutritional supplement with potential applications in metabolic support and clinical nutrition. Future evidence-based investigations should determine its effectiveness in improving nutritional status, glycemic control, gastrointestinal tolerance, inflammatory responses, and functional recovery.